Remove Article Remove Regulations Remove Testimonials
article thumbnail

New FDA guidance on addressing misinformation under White House review

Agency IQ

BY LAURA DIANGELO, MPH A new question-and-answer draft guidance document focused on “addressing misinformation” about regulated life sciences products is currently under administrative review at the White House’s Office of Information and Regulatory Affairs (OIRA). Fill out the form to read the full article.

FDA 59
article thumbnail

Bogus ‘Cure’ Claims Have U.S. Consumers Snapping Up CBD Products

The Pharma Data

“This article is a valuable contribution because it simply observes the state of things, but to go a step further and say this is really bad because people aren’t doing what doctors want them to do is an opinion, not a fact,” said Bostwick, who was not part of the study. “This is an unknown territory. Source link.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Article FDA Thank You New FDA guidance on addressing misinformation under White House review

Agency IQ

New FDA guidance on addressing misinformation under White House review A new question-and-answer draft guidance document focused on “addressing misinformation” about regulated life sciences products is currently under administrative review at the White House’s Office of Information and Regulatory Affairs (OIRA).

FDA 40
article thumbnail

Analysis Chemical Thank You Senate hearing on hazardous substance listing for PFAS finds common ground, but disagreements on implementation tactics

Agency IQ

The testimony of witnesses and the Senators themselves largely agreed on the designation, but diverged on questions of liability exemptions. How the agency plans to regulate PFAS via CERCLA In late 2021, the EPA published the PFAS Strategic Roadmap , which laid out the planned PFAS strategy for the agency between 2021 and 2024.

article thumbnail

Analysis Life Sciences Thank You The 51 regulations that FDA is currently working on

Agency IQ

The 51 regulations that FDA is currently working on The FDA today unveiled its much-anticipated Spring 2023 Unified Agenda, a document outlining the regulations the agency plans to release in 2023 and beyond. The anticipated date of publication is June 2023, meaning we should see this regulation imminently.

article thumbnail

Article FDA Thank You Explainer: What a government shutdown would mean for the FDA (Updated)

Agency IQ

In this piece, AgencyIQ explains what a government shutdown would mean for FDA’s regulatory processes and for the industry it regulates. AgencyIQ thought this would be a good time to go over what a government shutdown means for the FDA, and therefore what regulated industry needs to know. What are the impacts for regulated industry?

article thumbnail

Analysis Chemical Thank You Freedhoff testifies in front of Senate EPW over TSCA implementation

Agency IQ

SHELLEY MOORE CAPITO (R-WV) opened the testimony. Carper noted that the issues with how the EPA has implemented TSCA has led to “grievances” from both the chemical industry and environmental advocates, as the flow of chemicals to market and regulation of harmful chemicals has slowed. Opening Sen. TOM CARPER (D-DE) and Sen.